medigraphic.com
ISSN 2007-4360 (Print)
Asociación Mexicana de Periodontología, Colegio de Periodoncistas A.C

2016, Number 1

<< Back

Rev Mex Periodontol 2016; 7 (1)

Drug-induced gingival enlargements. A genomics and genetic view. Literature review

Zerón GVJA, Sautto TM

Language: Spanish
References: 45
Page: 25-35
PDF size: 345.84 Kb.


ABSTRACT

Medications that are associated with gingival enlargement can be divided into three categories: anticonvulsants, calcium channel blockers and immunosuppressants. Several risk factors can be currently recognized in the oral cavity that may precipitate gingival enlargement in response to gene expression and altered cellular mechanisms, where microbial biofilm can be a reservoir of precursor molecules.


REFERENCES

  2. Rees TD, Levine RA. Systemic drugs as a risk factor for periodontal disease initiation and progression. Compend Contin Educ Dent. 1995; 16: 20-42.

  3. Lewis IK, Hanlon JT, Schmader KE et al. Use of medications with potential oral adverse drug interactions in community dwelling elderly. Spec Care Dentist. 1993; 13: 171-176.

  4. Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowth. Aust Dent J. 1999; 44: 219-232.

  5. Dongari-Bagtzoglou A; Research, Science and Therapy Committee, American Academy of Periodontology. Drug-associated gingival enlargement. J Periodontol. 2004; 75 (10): 1424-1431.

  6. Charles NS, Chavan R, Moon NJ, Nalla S, Mali J, Prajapati A. Drug-induced gingival overgrowth: the genetic dimension. N Am J Med Sci. 2014; 6 (9): 478-480.

  7. Charles N, Ramesh V, Babu KS, Premalatha B. Gene polymorphism in amlodipine-induced gingival hyperplasia: a case report. J Young Pharm. 2012; 4: 287-289.

  8. Johnson RB, Zebrowski EJ, Dai X. Synergistic enhancement of collegenous protein synthesis by human gingival fibroblasts exposed to nifedipine and interleukin-1-beta in vitro. J Oral Pathol Med. 2000; 29: 8-12.

  9. Corręa JD, Queiroz-Junior CM, Costa JE, Teixeira AL, Silva TA. Phenytoin-induced gingival overgrowth: a review of the molecular, immune, and inflammatory features. ISRN Dent. 2011; 2011: 497850.

  10. Iacopino AM, Doxey D, Cutler CW, Nares S, Stoever K, Fojt J et al. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia. J Periodontol. 1997; 68: 73-83.

  11. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med. 1991; 20 (5): 201-209.

  12. Chung Y, Fu E, Chin YT, Tu HP, Chiu HC, Shen EC et al. Role of Shh and TGF in cyclosporine-enhanced expression of collagen and α-SMA by gingival fibroblast. J Clin Periodontol. 2015; 42 (1): 29-36.

  13. Lijnen P, Petrov V. Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find Exp Clin Pharmacol. 2002; 24 (6): 333-344.

  14. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 2007; 170 (6): 1807-1816.

  15. Sobral LM, Kellermann MG, Graner E, Martelli-Junior H, Coletta RD. Cyclosporin A-induced gingival overgrowth is not associated with myofibroblast transdifferentiation. Braz Oral Res. 2010; 24 (2): 182-188.

  16. Mariani G, Calastrini C, Carinci F, Marzola R, Calura G. Ultrastructural features of cyclosporine A-induced gingival hyperplasia. J Periodontol. 1993; 64: 1092-1097.

  17. Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000. 1999; 21: 176-196.

  18. Gürkan A, Becerik S, Öztürk VÖ, Atmaca H, Atilla G, Emingil G. Interleukin-6 family of cytokines in crevicular fluid of renal transplant recipients with and without cyclosporine a-induced gingival overgrowth. J Periodontol. 2014; 86 (9): 1069-1077.

  19. Gürkan A, Emingil G, Afacan B, Berdeli A, Atilla G. Alpha 2 integrin gene (ITGA2) polymorphism in renal transplant recipients with and without drug induced gingival overgrowth. Arch Oral Biol. 2014; 59 (3): 283-288.

  20. Türkoğlu O, Gürkan A, Emingil G, Afacan B, Töz H, Kütükçüler N et al. Are antimicrobial peptides related to cyclosporine A-induced gingival overgrowth? Arch Oral Biol. 2014; 60 (3): 508-515.

  21. Luo Y, Gong Y, Yu Y. Interleukin-10 gene promoter polymorphisms are associated with cyclosporin A-induced gingival overgrowth in renal transplant patients. Arch Oral Biol. 2013; 58 (9): 1199-1207.

  22. Gong Y, Lu J, Ding X. Clinical, microbiologic, and immunologic factors of orthodontic treatment-induced gingival enlargement. Am J Orthod Dentofacial Orthop. 2011; 140 (1): 58-64.

  23. Sardarian A, Andisheh-Tadbir A, Zal F, Amini F, Jafarian A, Khademi F et al. Altered oxidative status and integrin expression in cyclosporine A-treated oral epithelial cells. Toxicol Mech Methods. 2015; 25 (2): 98-104.

  24. De Oliveira-Costa F, Diniz-Ferreira S, de Miranda-Cota LO, da Costa JE, Aguiar MA. Prevalence, severity, and risk variables associated with gingival overgrowth in renal transplant subjects treated under tacrolimus or cyclosporin regimens. J Periodontol. 2006; 77: 969-975.

  25. Radwan-Oczko M, Boratyńska M, Zietek M, Zołedziewska M, Jonkisz A. The relationship of transforming growth factor-beta1 gene polymorphism, its plasma level, and gingival overgrowth in renal transplant recipients receiving different immunosuppressive regimens. J Periodontol. 2006; 77 (5): 865-873.

  26. Banthia R, Gupta S, Banthia P, Singh P, Raje S, Kaur N. Is periodontal health a predictor of drug-induced gingival overgrowth? A cross-sectional study. Dent Res J (Isfahan). 2014; 11 (5): 579-584.

  27. Grover V, Kapoor A, Mayra CM. Amlodipine induced gingival hyperplasia. J Oral Health Comm Dent. 2007; 1 (1): 19-22.

  28. Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR. Amlodipine-induced gingival overgrowth. J Clin Periodontol. 1994; 21: 281-283.

  29. Mironiuc-Cureu M, Dumitriu AS, Gheorghiu IM, Stoian IM. Gingival overgrowth as secondary effect of calcium channel blockers administration. A case report. J Med Life. 2014; 7 (2): 241-245.

  30. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol. 1996; 23 (3 Pt 1): 165-175.

  31. Alandia-Roman CC, Tirapelli C, Ribas P, Panzeri H. Drug-induced gingival overgrowth: a case report. Gen Dent. 2012; 60 (4): 312-315.

  32. Livada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. J Hum Hypertens. 2014; 28 (1): 10-14.

  33. Heasman PA, Hughes FJ. Drugs, medications and periodontal disease. Br Dent J. 2014; 217 (8): 411-419.

  34. Pari A, Ilango P, Subbareddy V, Katamreddy V, Parthasarthy H. Gingival diseases in childhood - a review. J Clin Diagn Res. 2014; 8 (10): ZE01-4.

  35. Omori K, Hanayama Y, Naruishi K, Akiyama K, Maeda H, Otsuka F et al. Gingival overgrowth caused by vitamin C deficiency associated with metabolic syndrome and severe periodontal infection: a case report. Clin Case Rep. 2014; 2 (6): 286-295.

  36. Pego SP, Coletta RD, Mendes DC, de Faria PR, Melo-Filho MR, Alves LR et al. Hereditary gingival fibromatosis: clinical and ultrastructural features of a new family. Med Oral Patol Oral Cir Bucal. 2015; 20 (2): e150-e155.

  37. Kapoor A, Malhotra R, Grover V, Saxena D. Pregnancy associated gingival enlargement. J Oral Health Comm Dent. 2010; 4 (2): 48-51.

  38. Hassell TM, Page RC, Narayanan AS, Cooper CG. Diphenylhydantoin (dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue. Proc Natl Acad Sci U S A. 1976; 73 (8): 2909-2912.

  39. Hassell TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med. 1991; 2 (1): 103-137.

  40. Dill RE, Miller EK, Weil T, Lesley S, Farmer GR, Iacopino AM. Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monocytes. J Periodontol. 1993; 64 (3): 169-173.

  41. Gong Y, Lu J, Ding X, Yu Y. Effect of adjunctive roxithromycin therapy on interleukin-1β, transforming growth factor-β1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth. J Periodontal Res. 2014; 49 (4): 448-457.

  42. Subramani T, Rathnavelu V, Alitheen NB. The possible potential therapeutic targets for drug induced gingival overgrowth. Mediators Inflamm. 2013; 2013: 639468.

  43. Trackman PC, Kantarci A. Molecular and clinical aspects of drug-induced gingival overgrowth. J Dent Res. 2015; 94 (4): 540-546.

  44. Lekkerkerker AN, Aarbiou J, van Es T, Janssen RA. Cellular players in lung fibrosis. Curr Pharm Des. 2012; 18 (27): 4093-4102.

  45. Carew RM, Wang B, Kantharidis P. The role of EMT in renal fibrosis. Cell Tissue Res. 2012; 347 (1): 103-116.




2020     |     www.medigraphic.com